Letter

Osteonecrosis of the jaw and bisphosphonates

BMJ 2006; 333 doi: 10.1136/bmj.39037.696759.3A (Published 23 November 2006)
Cite this as: BMJ 2006;333:1122.3

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

Editorial was confusing

  1. Mark J Bolland (m.bolland@auckland.ac.nz),
  2. Andrew Grey, associate professor of medicine,
  3. Ian R Reid, professor of medicine
  1. 1Department of Medicine, University of Auckland, Auckland, New Zealand

    The recent editorial by Landis et al has added confusion rather than clarity to the issue of osteonecrosis of the jaw (ONJ) in association with the use of bisphosphonates.1 They do not distinguish between the use of very high doses of intravenous bisphosphonates (monthly pamidronate or zoledronate) to treat patients with malignancy, and the use of much lower doses of bisphosphonates (approximately 1/12 of the oncology dose) in the treatment of Paget's disease or osteoporosis. These two different uses of bisphosphonates have been associated with different risks …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    Read related article

    See previous polls

    BMJ most popular